Akynzeo (Fosnetupitant and Palonosetron) and Buprenorphine Sublingual Tablets
Determining the interaction of Akynzeo (Fosnetupitant and Palonosetron) and Buprenorphine Sublingual Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using buprenorphine together with palonosetron can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Talk to your doctor if you have any questions or concerns. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether together or alone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).
MANAGEMENT: Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.
- EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):
- Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82
- Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
- Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8
Generic Name: fosnetupitant / palonosetron
Brand name: Akynzeo for injection
Synonyms: Fosnetupitant and palonosetron (injection), Fosnetupitant and Palonosetron
Generic Name: buprenorphine
Brand name: Probuphine, Belbuca, Buprenex, Butrans, Sublocade, Subutex
Synonyms: Buprenorphine (implant), Buprenorphine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Akynzeo (Fosnetupitant and Palonosetron)-Buprenorphine Transdermal
- Akynzeo (Fosnetupitant and Palonosetron)-Buprenorphine Transdermal Patch
- Akynzeo (Fosnetupitant and Palonosetron)-Buprenorphine transdermal skin patch
- Akynzeo (Fosnetupitant and Palonosetron)-Buprenorphine, Buprenorphine Hydrochloride
- Akynzeo (Fosnetupitant and Palonosetron)-Buprenorphine/naloxone Oromucosal, Sublingual
- Akynzeo (Fosnetupitant and Palonosetron)-Buproban
- Buprenorphine Sublingual Tablets-Akynzeo (Netupitant and Palonosetron)
- Buprenorphine Sublingual Tablets-Akynzeo for injection
- Buprenorphine Sublingual Tablets-Akynzeo Intravenous
- Buprenorphine Sublingual Tablets-Ala Hist IR
- Buprenorphine Sublingual Tablets-Ala Hist PE
- Buprenorphine Sublingual Tablets-Ala Quin Cream